Vaishali Pharma Ltd Stock Price Today (NSE: VAISHALI)
Fundamental Score
Vaishali Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vaishali Pharma Ltd share price today is ₹6.98, down 0.71% on NSE/BSE as of 18 June 2026. Vaishali Pharma Ltd (VAISHALI) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹94.01 (Cr). The 52-week high for VAISHALI share price is ₹13.59 and the 52-week low is ₹4.75. The company has a Return on Equity (ROE) of 1.52% and a debt-to-equity ratio of 0.23.
Vaishali Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Vaishali Pharma Ltd share price chart: -12.07% return over the past month. 52-week high ₹13.59, 52-week low ₹4.75.
Vaishali Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹7.03 | ₹7.03 | ₹6.81 | ₹6.98 | 58.43K (Cr) | |
| ₹7.29 | ₹7.29 | ₹7.00 | ₹7.03 | 54.93K (Cr) | |
| ₹7.14 | ₹7.42 | ₹6.96 | ₹7.05 | 1.53L (Cr) | |
| ₹7.22 | ₹7.22 | ₹7.01 | ₹7.14 | 67.88K (Cr) | |
| ₹7.30 | ₹7.30 | ₹6.94 | ₹7.05 | 48.34K (Cr) | |
| ₹7.14 | ₹7.14 | ₹6.86 | ₹7.05 | 39.99K (Cr) | |
| ₹7.05 | ₹7.05 | ₹6.92 | ₹7.00 | 35.78K (Cr) | |
| ₹6.90 | ₹7.23 | ₹6.82 | ₹6.99 | 51.77K (Cr) | |
| ₹6.91 | ₹7.07 | ₹6.75 | ₹6.93 | 45.29K (Cr) | |
| ₹6.87 | ₹7.05 | ₹6.87 | ₹6.97 | 30.20K (Cr) |
Vaishali Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹7.29 | ₹7.29 | ₹6.81 | ₹6.98 | -4.25% | |
| ₹7.76 | ₹7.90 | ₹6.72 | ₹7.05 | -9.15% | |
| ₹5.00 | ₹9.30 | ₹5.00 | ₹7.61 | +52.20% | |
| ₹7.19 | ₹7.19 | ₹4.75 | ₹4.88 | -32.13% | |
| ₹8.05 | ₹8.30 | ₹6.81 | ₹6.97 | -13.42% | |
| ₹8.83 | ₹9.80 | ₹7.93 | ₹7.97 | -9.74% | |
| ₹8.85 | ₹9.78 | ₹7.75 | ₹8.62 | -2.60% | |
| ₹10.19 | ₹10.27 | ₹8.51 | ₹8.79 | -13.74% | |
| ₹11.55 | ₹11.88 | ₹9.00 | ₹10.04 | -13.07% | |
| ₹12.30 | ₹12.70 | ₹11.12 | ₹11.31 | -8.05% | |
| ₹12.26 | ₹13.10 | ₹11.85 | ₹12.24 | -0.16% | |
| ₹11.83 | ₹13.59 | ₹11.27 | ₹12.34 | +4.31% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Vaishali Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vaishali Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VAISHALI across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Revenue Growth (60.89%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (93.18% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (93.79% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.23)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (1.52%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (4.93%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-40.10%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (0.83x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-14.52 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (26.32%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vaishali Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Vaishali Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
30.2/100 | ₹6.98₹7 | ₹94.01₹94.01 | — — | 1.52%Poor 1.52% Poor | 4.93%Poor 4.93% Poor | 0.23Excellent 0.2 Excellent | 93.79%Excellent 93.79% Excellent | 10.51%Good 10.51% Good | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Vaishali Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for VAISHALI — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.06 | ₹17.49 | 273.3x |
| FY 2023 | ₹0.59 | ₹18.20 | 30.8x |
| FY 2022 | ₹0.38 | ₹13.87 | 36.3x |
| FY 2021 | ₹0.10 | ₹3.58 | 36.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Vaishali Pharma Ltd Quarterly Performance
Latest quarterly metrics for VAISHALI — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
60.89%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-40.10%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.51%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
93.79%
Compounded annual net profit growth over 5 years
Vaishali Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VAISHALI — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Vaishali Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Vaishali Pharma Ltd (VAISHALI) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Vaishali Pharma Ltd
About VAISHALI (Vaishali Pharma Ltd)
Vaishali Pharma Ltd is a dynamic pharmaceutical company committed to developing, manufacturing, and distributing a wide range of high-quality pharmaceutical products. Focused on im...proving patient health and well-being, Vaishali operates with a dedication to innovation, scientific rigor, and ethical practices. The company strives to meet the evolving healthcare needs of communities globally by offering a comprehensive portfolio of medications. Vaishali Pharma is dedicated to creating affordable and accessible solutions for various medical conditions. Through continuous research and development, state-of-the-art manufacturing facilities, and a strong commitment to quality, Vaishali Pharma aspires to be a trusted partner in healthcare. Vaishali Pharma's product line encompasses an extensive array of therapeutic categories designed to address a multitude of health concerns. The company produces and markets essential drugs covering areas such as infectious diseases, pain management, respiratory illnesses, cardiovascular health, and metabolic disorders. Vaishali’s broad portfolio includes both generic medications and specialized formulations, ensuring a wide reach and accessibility for patients. Committed to maintaining the highest standards, Vaishali Pharma adheres to stringent quality control measures throughout the production process, from raw material sourcing to final product packaging. This commitment guarantees that all products are safe, effective, and meet the rigorous requirements of regulatory bodies. Vaishali Pharma's global reach extends to numerous markets, allowing it to make a significant impact on healthcare systems around the world. The company is dedicated to expanding its presence through strategic partnerships, innovative product development, and a steadfast focus on customer satisfaction. Vaishali emphasizes strong relationships with healthcare professionals, distributors, and regulatory agencies to ensure its medications reach those who need them most. By fostering a culture of excellence and continuous improvement, Vaishali Pharma strives to remain at the forefront of the pharmaceutical industry, constantly seeking new ways to improve patient outcomes and contribute to a healthier future.
Company Details
Key Leadership
Latest News
VAISHALI Share Price: Frequently Asked Questions
What is the current share price of Vaishali Pharma Ltd?
Vaishali Pharma Ltd (VAISHALI) trades at ₹6.98 on NSE. Market cap ₹94.01 (Cr). Educational data only.
What is the P/E ratio of Vaishali Pharma Ltd?
Vaishali Pharma Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Vaishali Pharma Ltd?
Vaishali Pharma Ltd has a Bull Run score of 30.2/100 based on 25+ financial parameters.
Does Vaishali Pharma Ltd pay dividends?
Vaishali Pharma Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Vaishali Pharma Ltd?
Vaishali Pharma Ltd has ROE of 1.52%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Vaishali Pharma Ltd?
Vaishali Pharma Ltd has debt-to-equity of 0.23.
Is Vaishali Pharma Ltd a good investment?
Bull Run gives Vaishali Pharma Ltd a score of 30.2/100. This is not investment advice — consult a SEBI-registered advisor.